Allogene Therapeutics (ALLO) vs Cabaletta Bio (CABA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed Cabaletta Bio (CABA) over the past year, losing 49.0% versus a loss of 55.0%. Over five years, CABA leads with a -91.9% price change compared with -96.5% for ALLO. Allogene Therapeutics is the larger company by market cap ($217.5 million vs $201.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | CABA |
|---|---|---|
| Share price | $0.6277 | $0.9361 |
| Market cap | $217.48M | $201.94M |
| 1-day change | -5.88% | -7.32% |
| YTD return | -54.18% | -57.26% |
| 1-year return | -48.97% | -55.00% |
| 5-year return | -96.51% | -91.93% |
| EPS (TTM) | $-0.61 | $-1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-190.89M | $-167.86M |
| 52-week high | $4.46 | $4.23 |
| 52-week low | $0.6192 | $0.93 |
| Distance from 52-week high | -85.93% | -77.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1333.81% | +1155.21% |
| Average volume | 7.69M | 5.15M |
| Shares outstanding | 346.47M | 215.72M |
| Employees | 150 | 154 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
ALLO vs CABA FAQ
Which is bigger, Allogene Therapeutics or Cabaletta Bio?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $217.48M compared with $201.94M for Cabaletta Bio (CABA).
Which stock has performed better over the past year, ALLO or CABA?
ALLO returned -48.97% over the past 12 months, compared with -55.00% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Cabaletta Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.